The imidazoline I 2 receptor ligand BU99006 binds to and attenuates effects mediated by I 2 receptors in vitro, although its effects in vivo have not been studied previously. This study examined the effects of BU99006 in two behavioral assays in rats: hypothermia and 2-BFI discrimination. BU99006 (3.2-15 mg/kg, intraperitoneally) produced a dose-dependent hypothermic effect (rectal temperature), which was antagonized by the I 2 receptor antagonist idazoxan. BU99006 (3.2 or 10 mg/kg administered 10 min or 2 h before the session, respectively) did not significantly alter hypothermia produced by the I 2 receptor agonist 2-BFI (10 mg/kg). In rats discriminating 5.6 mg/kg 2-BFI, BU99006 (1.78-17.8 mg/kg, intraperitoneally) produced 40 and 82% responding on the 2-BFI-associated lever when it was administered immediately or 2 h before the test sessions, respectively. BU99006 enhanced the discriminative stimulus and rate-suppressing effects of 2-BFI. Collectively, these data suggest that BU99006 is an imidazoline I 2 receptor agonist with no evidence of I 2 receptor antagonism in rats. Behavioural
Introduction
The concept of imidazoline-binding sites was first proposed in 1984 (Bousquet et al., 1984) ; subsequent research has focused on understanding the nature of these binding sites (Regunathan and Reis, 1996; Head and Mayorov, 2006) . Initially, they were believed to recognize compounds with an imidazoline moiety; however, we now know that some compounds with no imidazoline structure also have high affinities for these binding sites (Nikolic and Agbaba, 2012) . In addition, there appear to be at least three different imidazoline receptor subtypes, each of which has unique pharmacological properties (Eglen et al., 1998) . For example, I 1 receptors have been shown to be involved in the central control of blood pressure, glucose balance, and metabolism (Head and Mayorov, 2006; Sun et al., 2007) , and a gene that encodes I 1 receptors (imidazoline receptor antisera-selected gene/nischarin) has been cloned (Sun et al., 2007) . The molecular identities (e.g. related gene, protein, and signaling substrates) of another subtype of imidazoline receptor (I 3 ) have not been confirmed, although pharmacological studies suggest that I 3 receptors might participate in pancreatic insulin secretion (Eglen et al., 1998; Morgan and Chan, 2001) .
Imidazoline I 2 receptors might be the most interesting of the imidazoline receptor subtypes because they are emerging as a possible drug target for some neurological and psychiatric disorders, such as pain, stroke, and drug abuse Garau et al., 2013) . I 2 receptors have not been cloned, although ligands selective for I 2 receptors have been used to study this receptor system. I 2 receptors were first believed to be nonadrenergic receptors that bind 3 H-idazoxan with high affinity and 3 H-para-aminoclonidine and 3 H-clonidine at much lower affinity (Regunathan and Reis, 1996) . When it became clear that these ligands were binding to both I 2 receptors and a 2 adrenoceptors, medicinal chemistry efforts focused on improving the ligand selectivity for I 2 receptors over a 2 adrenoceptors. Several highly selective I 2 receptor ligands were developed and pharmacological studies suggest possible therapeutic benefits of these compounds (Hudson et al., 2003; Nikolic and Agbaba, 2012) . For example, I 2 receptor agonists consistently produce robust antinociceptive effects in various rodent models of acute and chronic pain (Ferrari et al., 2011; Meregalli et al., 2012; Sampson et al., 2012) . In both rats and mice, these agonists also produce effects similar to drugs used in humans for their antidepressant effects Hudson et al., 2003; Meregalli et al., 2012; Tonello et al., 2012) . Thus, I 2 receptor agonists might be useful for treating a broad range of disorders, including some of the most treatment-resistant neurological and psychiatric disorders, such as neuropathic pain and depression. Additional studies aimed at improving our understanding of the I 2 receptor system are warranted.
One significant challenge when studying the I 2 receptor system is that no selective I 2 receptor antagonists are available. Although some drugs, such as idazoxan (Sánchez-Blázquez et al., 2000; Thorn et al., 2012; Tonello et al., 2012) and BU224 (Sánchez-Blázquez et al., 2000; Bhalla et al., 2013) have been shown to attenuate the effects of I 2 receptor agonists such as 2-BFI and CR4056, these compounds have also been shown to have agonist effects in some assays, suggesting that they have low efficacy at I 2 receptors. For example, both 2-BFI and BU224 increase rotational behaviors in rats with nigrostriatal lesions (Macinnes and Duty, 2004) , and in drug discrimination studies, both idazoxan and BU224 produce responding predominantly on the 2-BFI-associated lever in rats (Jordan et al., 1996; MacInnes and Handley, 2002) . Thus, idazoxan and BU224 appear to be agonists in some assays and antagonists in others, suggesting that these drugs have lower efficacy at I 2 receptors compared with other ligands. In this context, a neutral I 2 receptor antagonist would be a useful tool to facilitate the understanding of I 2 receptor pharmacology.
BU99006 is an analog of the prototypic I 2 receptor ligand 2-BFI. In competition binding studies, BU99006 inhibits the binding of 3 H-2-BFI (Tyacke et al., 2002) in both rats and mice (Tyacke et al., 2002; Garcia-Sevilla and Ferrer-Alcon, 2003) . After peripheral administration, BU99006 readily enters the brain and binds in a pattern similar to that of 2-BFI (Paterson et al., 2007) . Although BU99006 binds selectively to I 2 receptors, its efficacy at these receptors has not been determined; however, to the extent that BU99006 has little or no efficacy, it might be a useful tool for selectively blocking other I 2 receptor ligands (Tyacke et al., 2002) . This study examined the effects of BU99006, alone and in combination with the I 2 receptor agonist 2-BFI, in two behavioral assays that are sensitive to I 2 receptor agonists: hypothermia and 2-BFI discrimination (MacInnes and Handley, 2002; Thorn et al., 2012) . If BU99006 is an I 2 receptor antagonist, it would be expected that it would not produce hypothermia or increase 2-BFI-associated lever responding, which I 2 receptor agonists do (MacInnes and Handley, 2002; Thorn et al., 2012) , but would instead attenuate the effects of 2-BFI in these assays.
Methods Subjects
A total of 49 adult male Sprague-Dawley rats (Harlan, Indianapolis, Indiana, USA) were studied [body temperature studies: 41 rats (n = 5-6 per group); drug discrimination: eight rats]. Rats used in body temperature studies were housed individually on a 12/12-h light/dark cycle with free access to water and food, except during experimental sessions, which were conducted during the light period. The body weights of the rats in the drug discrimination study were maintained at 85% of their free-feeding body weight by adjusting the amount of standard rodent chow that was provided in the home cage after daily sessions. Animals were maintained and experiments were conducted in accordance with the Institutional Animal Care and Use Committee, University at Buffalo, the State University of New York, and with the Guide for the Care and Use of Laboratory Animals (11th ed., Institute of Laboratory Animal Resources on Life Sciences, National Research Council, National Academy of Sciences, Washington, DC, USA).
Body temperature
Body temperature was measured in a quiet procedure room maintained under environmental conditions (temperature, humidity, and lighting) that were identical to those in the animal colony room. Rats were handled for at least 3 days before testing drugs to habituate them to the procedure, and they were habituated to the procedure room for at least 30 min before each test. Body temperature was measured by gently inserting a rectal probe (5.0 cm) and recording temperature from the digital thermometer (BAT7001H; Physitemp Instruments Inc., Clifton, New Jersey, USA) (Li et al., 2009; Thorn et al., 2012) . Each rat was used to study only one drug dose or combination test. A test session in which saline was administered was always conducted before a test session in which drug was administered. For each test session, body temperature was measured immediately before drug administration and every 15 min after drug was administered until the effect of the drug was no longer evident or until 3.5 h had elapsed since drug administration. BU99006 was studied alone and in combination with 2-BFI or idazoxan. For drug combination studies, BU99006 was administered 10 min (3.2 mg/kg) or 2 h (10 mg/kg) before the first measurement of body temperature, which was followed immediately by the administration of either 2-BFI or idazoxan, and body temperature was then measured every 15 min as described above. The 2-h pretreatment time was chosen because it was necessary to wait until the hypothermic effect of BU99006 dissipated before administration of 2-BFI.
Drug discrimination
Drug discrimination studies were carried out in commercially available two-lever operant chambers located within sound-attenuating, ventilated enclosures (Coulbourn Instruments Inc., Allentown, Pennsylvania, USA). Data were collected through an interface using Graphic State 3.03 software (Coulbourn Instruments Inc.) (Li et al., 2013) . The experimental protocol has been described in detail elsewhere (Li et al., 2013) . Briefly, daily sessions consisted of a 10-min timeout period, followed by a 10-min response period. During the timeout period, the chamber was dark and lever presses had no programmed consequence; during the response period, the stimulus lights above both levers were illuminated and 10 consecutive responses [fixed ratio (FR) 10] on the correct lever resulted in the delivery of a food pellet (45 mg; BioServ Inc., Frenchtown, New Jersey, USA). A response on the incorrect lever reset the FR requirement on the correct lever. The response period ended after 10 min or the delivery of 20 food pellets, whichever occurred first.
For training sessions, saline or 5.6 mg/kg 2-BFI was injected (intraperitoneally) at the start of the timeout period 10 min before the response period. When rats received saline, only responding on the saline lever resulted in food delivery. When rats received 2-BFI, only responding on the drug lever resulted in food delivery. Sessions were conducted 7 days/week, with the order of training sessions generally following a double-alternation schedule (e.g. saline, saline, drug, drug).
Test sessions began when rats fulfilled the following criteria for five consecutive training sessions or for six out of seven training sessions: at least 90% of the total responses occurring on the correct lever, on the basis of the injection administered before the session, and fewer than 10 responses (1 FR) occurring on the incorrect lever before delivery of the first food pellet. After the first test session, these criteria were fulfilled for the two consecutive training sessions immediately before each test. Test sessions were identical to training sessions, except that 10 consecutive responses on either lever resulted in the delivery of food; on separate occasions, varying doses of 2-BFI or BU99006 alone were administered immediately before the session. When the BU99006 and 2-BFI drug combinations were studied, BU99006 was administered 10 min or 2 h before 2-BFI. The order of tests with 2-BFI and BU99006 varied nonsystematically among the animals.
Drugs
The compounds studied were 2-BFI hydrochloride [2-(2benzofuranyl)-2-imidazoline hydrochloride] and BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline), which were synthesized at the Research Triangle Institute and verified by high-performance liquid chromatography (> 95% pure), nuclear magnetic resonance and elemental analysis, and idazoxan hydrochloride (Sigma-Aldrich, St Louis, Missouri, USA). Drugs were dissolved in 0.9% physiological saline and administered intraperitoneally. BU99006 powder was stored at -201C and the solution was prepared before tests. Doses are expressed as milligrams of the form indicated above per kilogram of body weight. Injection volumes were 1 ml/kg.
Data analyses
Changes in body temperature (1C, mean±SEM) were calculated by subtracting the first measurement of body temperature during each test session from all the subsequent measurements, which were then plotted as a function of time. Drug interactions were analyzed using two-way repeated-measures analysis of variance (ANOVA) (time Â treatment), followed by Newman-Keuls's post-hoc test. A P value of less than 0.05 was considered statistically significant.
Two dependent variables were collected during drug discrimination sessions: (a) the percentage of responses on the 2-BFI-associated lever, calculated by dividing the number of responses on the 2-BFI-associated lever by the total number of responses on both levers and multiplying by 100; and (b) response rate, calculated by dividing the total number of responses made on both levers by the duration of the response period in seconds. When a rat responded at a rate that was less than 20% of the vehicle control rate (the rate that was collected after saline was administered), the percentage of responses on the 2-BFIassociated lever for that dose or dose combination was not included for further analysis, although the response rate data were included. The mean percentage of responses on the 2-BFI-associated lever±1 SEM and the mean rate of responding±1 SEM during test sessions were plotted as a function of dose. One-way (as compared with vehicle data) or two-way repeated-measures ANOVA (2-BFI dose Â BU99006 treatment), followed by Newman-Keuls's posthoc test was used to analyze the effects of BU99006 on 2-BFI discrimination. The paired Student's t-test was used to compare the difference when only two data points were available. When appropriate, the ED 50 values (95% confidence intervals) were estimated using linear regression. A P value of less than 0.05 was considered statistically significant.
Results

Body temperature
BU99006 dose dependently decreased body temperature in rats (Fig. 1a) . A dose of 3.2 mg/kg of BU99006 was ineffective, whereas a larger dose markedly reduced body temperature. The maximum decrease produced by 10 mg/kg was -2.2±0.121C (mean±SEM), which was obtained 30 min after administration, and the effect lasted for 2.5 h. A dose of 15 mg/kg BU99006 further decreased body temperature to -2.8±0.151C 30 min after administration, with a duration of action of 3 h. A dose of 10 mg/kg 2-BFI also markedly reduced body temperature (-2.0±0.071C, Fig. 1b ). This dose of 2-BFI was also studied in combination with BU99006. A small dose of BU99006 that did not alter body temperature when administered alone also did not alter the hypothermic effects produced by 10 mg/kg 2-BFI. Two-way ANOVA showed a significant interaction [F (11, 110) = 2.54, P < 0.01], but there was no significant main effect of BU99006 treatment [F (1, 110) = 0.90]. Post-hoc analysis showed no significant differences across the time points studied. A larger dose of BU99006 was administered 2 h before 2-BFI and this dose also did not significantly modify the hypothermic effects of 2-BFI ( Fig. 1b) . Two-way ANOVA showed a significant interaction [F (11, 110) = 2.34, P <0.05], but there was no significant main effect of BU99006 treatment [F (1, 110) = 1.50]. Post-hoc analysis showed no significant differences across the time points studied. A dose of 3 mg/kg of the adrenergic a 2 receptor/imidazoline I 2 receptor antagonist idazoxan significantly attenuated the hypothermic effects of 10 mg/kg BU99006 (Fig. 1c) . Two-way ANOVA showed a significant interaction [F (9, 81) = 2.80, P < 0.01] and a significant main effect of idazoxan treatment [F (1, 81) = 11.0, P < 0.01]. Post-hoc analysis showed that the hypothermic effects of BU99006 were significantly smaller in rats that received a combination of 3 mg/kg idazoxan and 10 mg/kg BU99006 as compared with rats that received BU99006 alone at the 30-90 min time period.
Drug discrimination
In rats discriminating 5.6 mg/kg 2-BFI from vehicle, 2-BFI dose dependently increased responding on the 2-BFI-associated lever (Fig. 2a) , with the training dose generating an average of 99.4±0.6% 2-BFI-associated lever responding [ED 50 (95% confidence interval) = 2.26 (1.63, 3.12) mg/kg]. One-way repeated-measures ANOVA on response rate showed that 2-BFI dose dependently decreased the response rate [F (5, 47) = 12.66, P < 0.001], with rates significantly suppressed at a dose of 10 mg/kg. When administered immediately before test sessions, BU99006 dose dependently increased responding on the 2-BFI-associated lever up to an average of 40.0±24.5% at a dose of 5.6 mg/kg. One-way repeated-measures ANOVA on response rate showed that BU99006 dose dependently decreased response rate [F (4, 39) = 21.37, P < 0.001], with rates significantly suppressed at doses of 5.6 and 10 mg/kg. When administered 2 h before test sessions, BU99006 dose dependently increased responding on the 2-BFI-associated lever up to a maximum of 82.6±16.5% at a dose of 10 mg/kg. One-way repeated-measures ANOVA on response rate showed that BU99006 dose dependently decreased response rate [F (4, 39) = 27.52, P < 0.001], with rates significantly suppressed at doses of 10 and 17.8 mg/kg (Fig. 2c) . When administered 10 min before 2-BFI, 3.2 mg/kg BU99006 enhanced the effects of 1.78 mg/kg 2-BFI, increasing responding on the drug lever from 25.0±16.4% to 62.5±18.3%, although this increase did not reach statistical significance. Similarly, when administered 2 h before sessions, 10 mg/kg BU99006 significantly increased the effects of 1.78 mg/kg 2-BFI [t (7) = 3.4, P < 0.05] (Fig. 2b) . A dose of 10 mg/kg BU99006 significantly enhanced the rate-decreasing effects of 2-BFI. Two-way ANOVA showed a significant main effect of BU99006 treatment [F (1, 28) = 16.06, P < 0.01] and post-hoc analysis found that BU99006 significantly enhanced the rate-decreasing effects of 5.6 and 10 mg/kg 2-BFI ( Fig. 2d) . 
Discussion
The primary finding of this study was that BU99006 appears to be an I 2 receptor agonist with no evidence that it has antagonist activity. BU99006 produced a dosedependent hypothermia that was antagonized by the adrenergic a 2 receptor/imidazoline I 2 receptor antagonist idazoxan, suggesting that the effect was primarily mediated by I 2 receptors. In contrast, under conditions where BU99006 did not alter body temperature, it did not antagonize the hypothermic effects of 2-BFI, which argues against the notion that BU99006 might have antagonist activity. BU99006 significantly increased responding on the 2-BFI-associated lever and enhanced the discriminative stimulus effects of 2-BFI, which further supports the notion that BU99006 has I 2 receptor-positive efficacy. Taken together, these results provide behavioral evidence that BU99006 has agonist activity at imidazoline I 2 receptors and shares behavioral effects with the prototypical I 2 receptor agonist, 2-BFI.
BU99006 has high affinity and selectivity for I 2 receptors. Once BU99006 occupies these receptors, it produces a conformational change that prevents binding of other I 2 receptor ligands such as 2-BFI (Tyacke et al., 2002; Kimura et al., 2009) , which has been shown following in-vitro preincubation treatment or intravenous injection (Tyacke et al., 2002) . Although the binding property of BU99006 for I 2 receptors has been examined, the functional effects of BU99006 are not known. In contrast, it is clear that the prototypic I 2 receptor agonist 2-BFI can produce a variety of effects. For example, 2-BFI increases dopamine levels and facilitates dopamine release in the rat striatum (Sastre-Coll et al., 2001) . In rats with lesions in the nigrostriatal tract, 2-BFI increases rotational behaviors (Macinnes and Duty, 2004) . Rats also discriminate 2-BFI and this assay has high pharmacological selectivity such that only drugs with high imidazoline I 2 receptor binding affinity and positive efficacy produce responding on the 2-BFI-associated lever (Jordan et al., 1996; Handley, 2002, 2003) . 2-BFI produces antinociceptive effects in a rat writhing test that are antagonized by idazoxan . In addition, seven I 2 receptor agonists, including 2-BFI, have been shown to produce marked hypothermia in rats, an effect that is attenuated by the adrenergic a 2 receptor antagonist/I 2 receptor ligand idazoxan and not by the adrenergic a 2 receptor antagonist yohimbine, suggesting that the hypothermic effects of 2-BFI are mediated by imidazoline I 2 receptors (Thorn et al., 2012) . These data suggest that I 2 receptors mediate various behavioral effects. As such, the primary goal of this study was to examine the hypothesis that BU99006, as claimed in previous studies (Tyacke et al., 2002; Kimura et al., 2009) , could serve as an I 2 receptor antagonist.
BU99006 produced a dose-dependent hypothermic effect, which is similar to effects obtained with other I 2 receptor agonists (Thorn et al., 2012) . In the current study, the hypothermic effect produced by 10 mg/kg BU99006 was very similar to that produced by 10 mg/kg 2-BFI and this hypothermia was significantly attenuated by 3 mg/kg idazoxan. Since BU99006 has very low affinity at adrenergic a 2 receptors (Tyacke et al., 2002) , the fact that this hypothermic effect was blocked by the adrenergic a 2 receptor antagonist/I 2 receptor ligand idazoxan suggests a role of I 2 receptors. To examine the possibility that BU99006 might antagonize the effects of 2-BFI, a small dose of BU99006 (3.2 mg/kg) was studied in combination with 10 mg/kg 2-BFI. This dose alone did not significantly change body temperature in rats, and did not change the hypothermic effects of 2-BFI. The lack of effect of BU99006 on hypothermia produced by 2-BFI might be because this dose is too small to considerably decrease the available I 2 receptors. Consequently, a larger dose of 10 mg/kg BU99006 was also studied in combination with 2-BFI; this dose interacts with I 2 receptors, as evidenced by hypothermic effects that are attenuated by idazoxan. BU99006 was administered 2 h before 2-BFI treatment to allow the hypothermic effect of BU99006 to dissipate. As it binds irreversibly to I 2 receptors, BU99006 should remain on the receptors even after the hypothermic effect wanes; however, it did not significantly change the effects of 2-BFI. Thus, BU99006 does not antagonize the effects of 2-BFI; rather, it appears to be an I 2 receptor agonist with effects similar to those of 2-BFI.
A second attempt to examine the potential antagonist activity of BU99006 was made in rats discriminating 2-BFI. When administered alone immediately before the sessions, BU99006 produced 40% responding on the 2-BFI-associated lever up to the dose that markedly decreased response rates. When administered 2 h before sessions, BU99006 produced greater than 80% responding on the 2-BFI-associated lever. Not surprisingly, the potency of BU99006 for suppressing response rates was decreased two-fold when BU99006 was administered 2 h before the test sessions. Doses of 3.2 mg/kg (administered 10 min before test sessions) and 10 mg/kg BU99006 (administered 2 h before test sessions) only enhanced the discriminative stimulus effects of 2-BFI. Overall, the interaction between 2-BFI and BU99006 in 2-BFI discrimination rats seemed to be additive and no evidence of antagonism was observed. It should be noted that in both experiments, a maximum of 2 h was used as the pretreatment time, and this period might not be enough to reveal slowly emerging antagonist effects.
There are examples, notably the irreversible mu-opioid receptor antagonist b-funaltrexamine and pseudo-irreversible mu-receptor antagonist buprenorphine, where antagonist effects are not apparent until 24-48 h after the drugs are administered (Ward et al., 1982; Walker et al., 1995) . A longer pretreatment time would be necessary to reveal a similar slowly emerging antagonist effect.
Conclusion
In two behavioral assays sensitive to imidazoline I 2 receptor agonists, the effects of BU99006 were similar to those of 2-BFI, with no evidence of antagonism. In male Wistar rats, the half-life of BU99006 binding (5 mg/ kg administered intravenously) is 4.3 h (Paterson et al., 2007) , which is consistent with the duration of the hypothermic effects observed in the current study and does not seem to support the claim of irreversible binding. Since the hypothermic effect of BU99006 was antagonized by idazoxan, these data suggest that BU99006 is an imidazoline I 2 receptor agonist with an efficacy similar to that of 2-BFI and higher efficacy than idazoxan.
